Transgene SA (OTCMKTS:TRGNF – Get Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totaling 1,095 shares, a growth of ∞ from the April 30th total of 0 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
Transgene Price Performance
Shares of TRGNF stock remained flat at $0.85 during trading hours on Tuesday. Transgene has a 52 week low of $0.85 and a 52 week high of $1.08. The firm has a fifty day moving average price of $0.93 and a two-hundred day moving average price of $0.95.
About Transgene
Transgene is a clinical-stage biotechnology company headquartered in Strasbourg, France, dedicated to designing and developing targeted immunotherapies for cancer and infectious diseases. Founded in 1979, the company combines expertise in virology, gene engineering and immunology to create viral-based vectors that deliver therapeutic genes or antigens directly into patient tissues. In the United States, Transgene’s American Depositary Receipts trade under the symbol TRGNF.
The company’s proprietary platforms include an oncolytic vaccine technology that harnesses genetically modified viruses to selectively infect and destroy tumor cells while stimulating systemic anti-tumor immunity.
Read More
- Five stocks we like better than Transgene
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
